Thoroughbred Financial Services, LLC Biogen Inc. Transaction History

Thoroughbred Financial Services, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$223.92 - $287.77 $216,306 - $277,985	-966 Closed	0 $0
Q3 2021 Oct 27, 2021	SELL	$282.99 - $369.05 $48,108 - $62,738	-170 Reduced 14.96%	966 $273,000
Q2 2021 Jul 27, 2021	BUY	$259.0 - $414.71 $294,224 - $471,110	1,136 New	1,136 $393,000
Q4 2020 Jan 26, 2021	SELL	$236.26 - $355.63 $203,892 - $306,908	-863 Closed	0 $0
Q3 2020 Oct 28, 2020	BUY	$264.77 - $305.71 $228,496 - $263,827	863 New	863 $244,000
Q2 2020 Jul 20, 2020	SELL	$258.66 - $342.55 $209,255 - $277,122	-809 Closed	0 $0
Q1 2020 Apr 23, 2020	BUY	$268.85 - $341.04 $29,842 - $37,855	111 Added 15.9%	809 $256,000
Q4 2019 Feb 05, 2020	BUY	$220.06 - $304.07 $153,601 - $212,240	698 New	698 $207,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Thoroughbred Financial Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Thoroughbred Financial Services, LLC with notifications on news.